Document is current

Article History

Received: 27 March 2024

Accepted: 25 April 2024

First Online: 6 May 2024

Declarations

:

: Ethical approval was waived by the local ethical committee due to the retrospective nature of this study. All procedures performed in this article were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients submitted to 5-ALA FGR were informed about the off-label character of the compound and provided informed consent. All cases were discussed and approved by interdisciplinary neuro-oncological tumor board.

: Informed consent was obtained from all individual participants submitted to 5-ALA FGR included in the retrospective series of this study.

: The author confirms that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any; that its publication has been approved (tacitly or explicitly) by the responsible authorities at the institution where the work is carried out.

: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers? bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.